{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Foncologypodcast.simplecast.com%2Fepisodes%2Fbsabs-in-rrmm-key-updates-t9QTrOrq","width":444,"version":"1.0","type":"rich","title":"Bispecific Antibody Therapy in Relapsed/Refractory Multiple Myeloma: Key Updates From the Annual Hematology Meeting","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/165defb8-f7d7-44fe-a7eb-a59f2c35d334/6f5b61e2-7891-4a02-8de7-1d637cbcda1b/7231-myeloma-bispecifics-collab-nccn-3000x3000.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"<iframe src=\"https://player.simplecast.com/c0570fbb-a755-4d0a-a022-3402a8878cea\" height=\"200\" width=\"100%\" title=\"Bispecific Antibody Therapy in Relapsed/Refractory Multiple Myeloma: Key Updates From the Annual Hematology Meeting\" frameborder=\"0\" scrolling=\"no\"></iframe>","height":200,"description":"Listen to this expert overview of the most interesting findings related to the clinical use of bispecific antibody therapy for relapsed/refractory multiple myeloma that were presented at the 2024 annual American Society of Hematology meeting."}